SCHEMBL5433359

SCHEMBL5433359

O=C(Nc1cccc(/C=C/c2cnc(Nc3cccnc3)nc2)c1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.62
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
BTK Q06187 9/20 0.60
CSF1R P07333 5/20 0.59
BRAF P15056 2/20 0.59
LCK P06239 5/20 0.56
EPHX2 P34913 1/20 0.56
KIT P10721 1/20 0.55
KDR P35968 1/20 0.55
MAPK14 Q16539 1/20 0.55
RXFP1 Q9HBX9 1/20 0.53
BLK P51451 2/20 0.53
ALOX15 P16050 1/20 0.53
CASP1 P29466 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ABL1 P00519 1/20 0.53
SRC P12931 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5433361 1.00 TSHR (0.62) TSHRMEN1KMT2ABTKCSF1R
SCHEMBL2491995 0.80 CSF1R (0.84) BTKCSF1RBRAFLCKMAPK14
SCHEMBL2501240 0.80 CSF1R (0.69) TSHRMEN1KMT2ABTKCSF1R
SCHEMBL2496610 0.80 BTK (0.86) BTKCSF1RBRAFLCKKIT
SCHEMBL14490148 0.80 BTK (0.52) BTKCSF1RBRAFLCKKDR
SCHEMBL2494865 0.79 CSF1R (0.65) TSHRMEN1KMT2ABTKCSF1R
SCHEMBL5178391 0.78 MEN1 (1.00) TSHRMEN1KMT2ACSF1RBRAF
SCHEMBL22441864 0.76 MEN1 (0.66) TSHRMEN1KMT2ABRAFNPSR1
SCHEMBL22441867 0.76 MEN1 (0.66) TSHRMEN1KMT2ABRAFNPSR1
SCHEMBL22441667 0.76 PKM (0.72) TSHRMEN1KMT2ARXFP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
WO-2007056075-A2 SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS TARGEGEN, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations ABL1, KDR, BCR TSHR 1704/4885MEN1 1745/4885KMT2A 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.